Increased trimipramine plasma levels during fluvoxamine comedication.

Détails

ID Serval
serval:BIB_D760250B190B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Increased trimipramine plasma levels during fluvoxamine comedication.
Périodique
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
Auteur⸱e⸱s
Seifritz E., Holsboer-Trachsler E., Hemmeter U., Eap C.B., Baumann P.
ISSN
0924-977X (Print)
ISSN-L
0924-977X
Statut éditorial
Publié
Date de publication
1994
Peer-reviewed
Oui
Volume
4
Numéro
1
Pages
15-20
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
A depressive patient, a non-responder to trimipramine (TRI), was comedicated first with citalopram (CIT) and then with fluvoxamine (FLUV). Both the TRI-CIT and TRI-FLUV combination treatments led to a worsening of the depressive state and to the appearance of panic attacks. The addition of FLUV to TRI resulted in a twofold increase of the plasma levels of TRI and to a slight increase of its N-demethylated and 2-hydroxylated metabolites. These results suggest that the interaction between FLUV and TRI occurred at the level of cytochrome P-450IID6 and cytochrome P-450meph in this patient, phenotyped as an extensive metabolizer of both dextromethorphan and mephenytoin. The adverse effects were possibly due to (a) a pharmacokinetic interaction between CIT and FLUV with TRI and/or (b) alterations in serotonergic and/or dopaminergic neurotransmission.
Mots-clé
Aged, Citalopram/adverse effects, Citalopram/therapeutic use, Depressive Disorder/blood, Depressive Disorder/complications, Dextromethorphan/pharmacokinetics, Drug Interactions, Female, Fluvoxamine/adverse effects, Fluvoxamine/therapeutic use, Humans, Mephenytoin/pharmacokinetics, Phenotype, Trimipramine/adverse effects, Trimipramine/blood
Pubmed
Web of science
Création de la notice
01/03/2013 10:27
Dernière modification de la notice
20/08/2019 15:57
Données d'usage